PARLAR-02 Trial:Modified Transanal Drainage Tube Use for Preventing Anastomotic Leakage
NCT07036588 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 968
Last updated 2025-06-25
Summary
Surgical resection remains the primary treatment for rectal cancer, but the postoperative incidence of anastomotic leakage (AL) is relatively high. AL not only increases the medical burden on patients, prolongs hospital stays, raises the need for secondary surgery, and elevates perioperative mortality, but also increases the long-term risk of local recurrence and reduces survival rates. There is an urgent need for a simple, effective treatment method that minimizes the burden on patients to prevent anastomotic leakage.
The preoperative placement of a transanal drainage tube (TDT) is believed to effectively drain gas and feces from the intestinal lumen, thereby reducing intestinal pressure and alleviating tension at the anastomotic site, thus preventing AL. Previous studies have shown that traditional drainage tubes cannot effectively prevent leakage. Given the limitations of existing research on traditional TDTs, we plan to use a modified TDT (which allows postoperative irrigation and utilizes a balloon to block feces from adversely affecting the anastomosis) to conduct a randomized, parallel-controlled trial. This study aims to further investigate the role of the modified TDT in preventing and treating anastomotic leakage following rectal surgery
Conditions
- Anastomotic Leak
Interventions
- DEVICE
-
Modified Transanal Drainage Tube
Patients with rectal adenocarcinoma will undergo elective laparoscopic/robotic low anterior resection. After the anastomosis is completed and the air leak test is confirmed to be negative, a modified TDT (occlusive balloon catheter) will be inserted. The balloon will be placed 5 cm above the anastomosis and filled under laparoscopic visualization (approximately 25 ml) to slightly dilate the intestinal lumen and occlude the intestinal cavity (under laparoscopic monitoring to ensure it does not affect the blood supply of the intestine). The external part of the tube will be sutured to the perianal skin and further secured with a 3M transparent dressing on the outside. It will be connected to a drainage bag (with an inner diameter greater than 8 mm) and left in place for 7 days, or until the drainage function is lost due to obvious defecation around the anal tube, at which point the catheter will be removed.
Sponsors & Collaborators
-
Third Military Medical University
lead OTHER
Principal Investigators
-
WeiDong Tong · Army Medical University, China
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-07-01
- Primary Completion
- 2027-12-31
- Completion
- 2030-12-31
Countries
- China
More Related Trials
-
"Oncologic Results and Risk Factors for Recurrence in Patients With Locally Advanced Rectal Cancer and Pathologic Complete Response After Neoadjuvant Treatment. Results From an Observational Retrospective Multicenter Long-term Follow-up Study".
NCT05495308 ·Status: COMPLETED
-
Personalized Long-course Radiotherapy Plus Chemotherapy With or Without Immunotherapy for LARC: PALACE Study
NCT07020247 ·Status: RECRUITING ·Phase: PHASE3
-
A Translational Study for Locoregional Recurrence of T4 Colon Cancer
NCT06958926 ·Status: RECRUITING
-
Can We Save the Rectum by Watchful Waiting or TransAnal Surgery Following (chemo)Radiotherapy Versus Total Mesorectal Excision for Early REctal Cancer?
NCT02945566 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3
-
Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer
NCT02942563 ·Status: UNKNOWN ·Phase: PHASE2
-
A Pospective, Single-arm, Multicenter Clinical Trial Evaluating Preoperative Neoadjuvant mFOLFOX6 Chemotherapy in Combination With PD1 Monoclonal Antibody in MSS/pMMR Locally Advanced Rectal Cancer
NCT06688786 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Neoadjuvant Therapy for Locally Advanced Rectal Cancer
NCT06853769 ·Status: ACTIVE_NOT_RECRUITING ·Phase: EARLY_PHASE1
-
Preserving Left Colonic Artery During Radical Resection of Rectal Cancer
NCT03776370 ·Status: COMPLETED
-
Evaluation of the Efficacy and Safety of Interleucin-2 Combined With PD-1 Monoclonal Antibody and CAPOX in Preoperative Neoadjuvant Therapy for Mid-low Locally Advanced Rectal Cancer - a Single-center, Single-arm, Open-label Clinical Trail
NCT06108596 ·Status: COMPLETED ·Phase: PHASE2
-
Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy, HLX07and Serplulimab in LARC
NCT06542588 ·Status: RECRUITING ·Phase: PHASE2
-
Transanal Decompression Tube Versus Stent for Acute Malignant Left-sided Colonic and Rectal Obstruction
NCT02585271 ·Status: TERMINATED ·Phase: NA
-
Radiotherapy Plus CAPOX, and Iparomlimab and Tuvonralimab (QL1706) as Neoadjuvant Therapy for LARC
NCT07291401 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Local Excision of Clinical T3 Rectal Adenocarcinoma Showing Major Response(ycT0-1) After Neoadjuvant Chemoradiotherapy
NCT02490709 ·Status: UNKNOWN ·Phase: PHASE2
-
Local Excision Versus Total Mesorectal Excision In Pathological Complete Response (ypT0-1cN0) Mid- Or Low-Rectal Cancer After Neoadjuvant Therapy
NCT03548844 ·Status: UNKNOWN ·Phase: NA
-
Neoadjuvant Moderately Hypofractionated Radiotherapy Combined with Chemotherapy and Immunotherapy for High-risk LARC
NCT06599827 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence
NCT06120127 ·Status: RECRUITING ·Phase: PHASE2
-
SCRT Combined With Chemotherapy and Iparomlimab and Tuvonralimab in MSS or pMMR Patients With Locally Advanced Rectal Cancer
NCT06864013 ·Status: RECRUITING ·Phase: PHASE2
-
Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal Incontinence in Patients With Locally Advanced Rectal Cancer or Other Pelvic Cancer, the RESTORE Study
NCT04066894 ·Status: TERMINATED ·Phase: PHASE2
-
Total Neoadjuvant Chemoradiotherapy Plus Anti-PD-1 in Subperitoneal Patients With Locally Advanced Rectal CancerPatients With Locally Advanced Rectal Cancer: A Prospective, Single Arm, Exploratory Study
NCT05998122 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Reasons for Non-reversal of Temporary Stomas After Surgeries of Mid-low Rectal Cancer (NORESTO Study)
NCT06194708 ·Status: RECRUITING
-
Proximally Extended Resection for Rectal Cancer After Neoadjuvant Chemoradiotherapy
NCT02649647 ·Status: RECRUITING ·Phase: NA
-
Total Neoadjuvant Treatment Plus PD-1 in Mid-Low Locally Advanced Rectal Cancer
NCT04906044 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Total Neoadjuvant Therapy With PD-1 for Locally Advcancer Rectal Cancer
NCT07214142 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Rectal Artery Infusion Chemotherapy Combined With Anti-PD1 Antibody for MSS LARC
NCT05307198 ·Status: UNKNOWN ·Phase: PHASE2
-
Treatment of Rectal Cancer With Long-term Concurrent Chemoradiotherapy Combined With Camrelizumab
NCT06304545 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2